Humanigen, Inc.

HGENQ

US4448632038

Pharmaceuticals

Market Closed - OTC Markets Other stock markets 20:48:43 28/06/2024 BST			5-day change	1st Jan Change
0.000001 ^USD	-99.50%		-99.50%	-99.92%

05-01	Combined Hearing for Disclosure Statement and Plan Approved for Humanigen, Inc.	CI
04-12	Combined Liquidation Plan and Disclosure Statement Filed by Humanigen, Inc.	CI

Humanigen, Inc. Announces Retirement of Robert G. Savage from the Board of Directors

January 07, 2021 at 09:30 pm

On January 1, 2021, Robert G. Savage notified Humanigen, Inc. of his retirement from the company's board of directors, effective immediately.

Latest news about Humanigen, Inc.

Combined Hearing for Disclosure Statement and Plan Approved for Humanigen, Inc.	05-01	CI
Combined Liquidation Plan and Disclosure Statement Filed by Humanigen, Inc.	04-12	CI
Final DIP Financing Approved for Humanigen, Inc.	03-08	CI
Motion for Asset Sale Approved for Humanigen, Inc.	02-17	CI
Notice for Auction Cancellation Filed by Humanigen, Inc.	02-13	CI
Bidding Procedure Approved for Humanigen, Inc.	01-25	CI
19 treatment developer Humanigen files for Chapter 11 bankruptcy	01-04	RE
Motion for Asset Sale Filed by Humanigen, Inc.	01-04	CI
Humanigen, Inc. Filed for Bankruptcy	01-03	CI
Interim DIP Financing Approved for Humanigen, Inc.	01-03	CI
Xspray Pharma Names Chief Commercial Officer	15/09/23	MT
Humanigen, Inc. Announces Resignation of Edward Jordan as Chief Commercial Officer	14/09/23	CI
North American Morning Briefing : PCE Inflation -2-	31/08/23	DJ
North American Morning Briefing : Nasdaq Futures -2-	24/08/23	DJ
Humanigen, Inc.(OTCPK:HGEN) dropped from S&P TMI Index	28/07/23	CI
Sector Update: Health Care Stocks Steady in Late Afternoon Trading	25/07/23	MT
Sector Update: Health Care Stocks Steady Tuesday Afternoon	25/07/23	MT
Sector Update: Health Care	25/07/23	MT
Humanigen Issues 'Going Concern' Warning; Shares Hit 52-Week Low	25/07/23	MT
Humanigen, Inc. Announces Board Changes	25/07/23	CI
Humanigen, Inc.(OTCPK:HGEN) dropped from NASDAQ Composite Index	25/07/23	CI
Humanigen, Inc.(NasdaqCM:HGEN) dropped from Russell Microcap Value Index	23/06/23	CI
Humanigen, Inc.(NasdaqCM:HGEN) dropped from Russell 3000E Value Index	23/06/23	CI
Humanigen, Inc.(NasdaqCM:HGEN) dropped from Russell Microcap Growth Index	23/06/23	CI
Humanigen, Inc.(NasdaqCM:HGEN) dropped from Russell Microcap Index	23/06/23	CI

Humanigen, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing its portfolio of proprietary Humaneered anti-inflammatory immunology and immuno-oncology monoclonal antibodies. Its Humaneered technology platform is a method for converting existing antibodies (typically murine) into engineered, high-affinity human antibodies designed for therapeutic use, particularly with acute and chronic conditions. Its product candidate, lenzilumab, and its other product candidate, ifabotuzumab (iFab), are Humaneered monoclonal antibodies are Humaneered monoclonal antibodies. lenzilumab is used as a therapeutic for chronic myelomonocytic leukemia; for the prevention of acute graft versus host disease; and as a prophylactic companion for certain chimeric antigen receptor therapy (CAR-T) programs. The Company has developed or in-licensed targets or research antibodies, typically from academic institutions, and then applied its Humaneered technology to optimize them.

Sector

Pharmaceuticals

More about the company

	1st Jan change	Capi.
HUMANIGEN, INC.	-99.92%	119
CSL LIMITED	+2.99%	95.18B
SAMSUNG BIOLOGICS CO.,LTD.	-4.34%	37.55B
BIOGEN INC.	-10.41%	33.75B
UCB	+75.79%	28.2B
BIOMARIN PHARMACEUTICAL INC.	-14.61%	15.63B
INCYTE CORPORATION	-3.46%	13.63B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-12.31%	11.5B
ALTEOGEN INC.	+184.77%	10.81B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-54.13%	9.23B

Biopharmaceuticals

Humanigen, Inc.

Equities

HGENQ

US4448632038

Pharmaceuticals

Humanigen, Inc. Announces Retirement of Robert G. Savage from the Board of Directors

Latest news about Humanigen, Inc.

Chart Humanigen, Inc.

Company Profile

Income Statement Evolution

Quarterly earnings - Rate of surprise

Sector Biopharmaceuticals